The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy

Category Primary study
JournalNEUROMUSCULAR DISORDERS
Year 2019
This article has no abstract
Epistemonikos ID: 6ea75d5a7155b0aa3d60f94fd88e59ab3c38e373
First added on: Feb 11, 2025